Little is known about the reach and impact of collaborative care for depression outside of clinical trials.
A ll too often, what looks promising in randomized clinical trials with highly selected patient populations, additional resources, and substantial control of the intervention may not be feasible or as effective when implemented in the real clinical world. Although health care delivery and insurance leaders in Minnesota knew that collaborative care for depression was effective in randomized trials, they also recognized it was rarely being used. 1 A primary reason for this seemed to be that its key services, particularly encounters with care managers, were not reimbursable. Given this, health care delivery and insurance leaders worked together with the Institute for Clinical Systems Improvement (ICSI), a regional quality improvement organization, to provide a new payment model for clinics trained to provide collaborative depression care. These efforts resulted in an initiative called DIAMOND (Depression Improvement Across Minnesota: Offering a New Direction).
The DIAMOND initiative provided a unique opportunity to study the implementation of the collaborative care model for depression and examine its reach and impact on unenrolled patients. This examination is important because a growing emphasis on implementation of evidence-based treatment brings a responsibility to examine the degree of implementation and its intended and unintended effects. In addition, real-world implementation may involve sacrificing some fidelity to the model, leading to additional learnings about how implementation differs from previous randomized clinical trials and informing future endeavors to spread this treatment.
Because collaborating health care payers provided claims data for all insured patients receiving antidepressant medications, we had the opportunity to examine important questions about implementation, specifically: (1) Did DIA-MOND affect the percentage of patients receiving depression codes?; and (2) Since DIAMOND insurance payments were only for patients with certain depression codes, did DIA-MOND influence the use of those codes? (3) As a key feature of the collaborative care model is to intensify treatment when needed, were DIAMOND patients more likely to receive treatment intensification than others with depression? antidepressant medications for depression in a primary care clinic. Nearly all of the large health care payers in Minnesota (Blue Cross Blue Shield, HealthPartners, Medica, Preferred One, and UCare) sent deidentified data to the study team for insured members with a new prescription for an antidepressant (identified by national drug codes and/or generic product identifiers) during the period of the initiative's implementation, February 2008 through March 2011. Payer data indicated which patients had diagnoses of major depression [International Classification of Diseases, Ninth Revision (ICD9) codes 296.2 and 296.3], dysthymia (300.4), or depressive disorder, not elsewhere classified (311).
Design
The DIAMOND initiative has been described previously, 2-4 but its key features were adopted from the largest study of the collaborative care model for depression to date, the Improving Mood-Promoting Access to Collaborative Treatment study. 5 As such, the DIAMOND care model specified systematic patient follow-up and monitoring by trained on-site care managers who reviewed cases weekly with a consultant psychiatrist, consistent use of the PHQ9 6, 7 to monitor depression severity, treatment intensification for patients not improving, and depression relapse prevention for patients achieving remission. To study this complex initiative, both initiative and research leaders agreed on an implementation design that was minimally disruptive for participants yet vigorous enough to allow study of its effectiveness, resulting in a staggered implementation design. Over 2.5 years, the initiative was implemented in 75 clinics in 5 sequences that were 6 months apart.
Training was facilitated by ICSI and conducted for 6 months before implementation for each site. The involved staff at each clinic, including physicians, care managers, and care manager supervisors, met with ICSI for 4 face-to-face training sessions and 2 webinars that covered each component of the DIAMOND care model, such as patient health questionnaire 9 use, depression management, registry development and use, and the new roles of the care manager and consulting psychiatrist. In addition, care managers attended a 1.5-day training session just before implementation that focused on their role, workflow, and skill-building for motivational interviewing, behavioral activation, and handling difficult cases. Training materials included checklists for implementation, example clinical workflows, evidencebased guidelines, patient materials and brochures, and tools and scripts for each team member. Monthly care manager calls were conducted throughout DIAMOND implementation to facilitate sharing and discussing tools and processes that were working well, as well as challenges and frustrations. Each site was given ongoing feedback about their enrollment and outcomes for their own quality improvement work.
Payment for DIAMOND services was a flat monthly per-participant amount which was limited to patients who had major depression (ICD9 codes 296.2, 296.3) or dysthymia (300.4) and were seen in participating clinics. Depression not otherwise specified (NOS) (311) was excluded from reimbursement because guidelines for treating this diagnosis were lacking, and because the DIAMOND initiative wanted to encourage more precise depression diagnoses. Payment was independently negotiated between participating health plans and medical groups but billed using a common DIA-MOND-specific code that allowed tracking of patients recruited into DIAMOND care. Accordingly, patients were defined as having received DIAMOND care if there was a DIAMOND-specific billing code associated with their care in any given month.
Analysis
To be included in the main analyses, patients needed a diagnostic code for depression at least once during the observation period. Patients with prescriptions for antidepressants but without a depression diagnosis code were not included.
To determine whether DIAMOND influenced the percentage of patients diagnosed with depression, we calculated the proportion of all primary care patients who received depression diagnoses in each month in each sequence. We then tested for statistically significant differences preimplementation versus postimplementation by including a timexDIAMOND interaction term in a mixed linear regression model weighted by clinic size.
To determine whether the use of depression diagnostic codes was affected by DIAMOND, we restricted the analysis to patients with depression. We then counted the number of patients with ICD9 codes of 296.2, 296.3, or 300.4 in a given month divided by the total number of patients seen in all clinics that month.
To determine whether DIAMOND patients were more likely to receive treatment intensification, only patients seen in clinics after DIAMOND was implemented in one of these clinics were included. As our claims data did not provide information about dosage or days' supply, we defined treatment intensification as the dispensing of any new antidepressant medication observed in a 3-month period. This included either changing from one antidepressant to another or adding another antidepressant to the current regimen. The number of unique antidepressants dispensed for a patient in a 3-month period was counted, and treatment intensification occurred each time the number of unique antidepressants per patient increased relative to the previous 3-month period. A w 2 test was used to test for differences in having treatment intensification by receipt of DIAMOND care as indicated by a DIAMOND-specific billing code.
RESULTS
A total of 106,931 patients with a prescription for an antidepressant had 1,114,207 primary care visits at 75 clinics with 973 providers. Of these, 37,859 patients with antidepressant prescriptions without diagnoses of depression were excluded; the largest excluded group was 19,933 patients with generalized anxiety disorder, but not depression. Our final sample included 854,293 visits for 69,072 patients with depression, including 757,570 person-months of observation and a median person-month follow-up of 8 months (interquartile range, 3-16 mo) ( Table 1) . DIAMOND did not influence the percentage of patients receiving depression codes in primary care clinics ( Fig. 1) . Although there was a general increase in depression diagnoses over time, there was no additional observed increase after DIAMOND implementation. In fact, for all DIAMOND sequences combined, the slope of depression diagnoses was higher before DIAMOND implementation than following it (0.153 vs. 0.013, P < 0.001).
DIAMOND also did not influence providers' use of specific diagnostic codes for depression. As seen in Figure 2 , there was an increase in the use of the single episode major depression code (296.2), and a decrease in the use of depression not otherwise specified (311), but these changes were present before DIAMOND and continued afterward without apparent influence by DIAMOND implementation. There were no significant changes in the use of codes for recurrent major depression (296.3) or dysthymia (300.4).
DIAMOND patients were more likely to receive treatment intensification ( Table 2 ). Although 15.2% of the 2976 patients receiving DIAMOND care had at least 1 treatment intensification, 10.9% of the 44,347 non-DIAMOND patients seen after DIAMOND implementation had evidence of treatment intensification, a significant difference of P < 0.0001. Of those patients with any treatment intensification in either group, the vast majority of patients (78%-79%) had only one.
DISCUSSION
Despite significant changes in care delivery and reimbursement for patients with specific depression codes, DIAMOND did not appear to affect either rates of depression recognition or use of diagnostic codes, and the overall reach of DIAMOND was disappointingly small. Patients in DIAMOND did have more measurable episodes of treatment intensification than patients with depression treated outside of this collaborative care initiative, but this may have been an appropriate difference, as claims data do not include any measures of depression severity.
DIAMOND implementation did not affect how often depression was diagnosed. This finding is likely related to DIAMOND recruitment rates being much lower than anticipated, peaking at only 2.4% of potentially eligible patients, and resulting in low spread of the initiative. The reasons for this are likely multifactorial, and speak of the daunting task of effectively translating clinical research into practice. Despite the experience and support of ICSI, including significant training for clinical staff and payment changes to make collaborative care more financially feasible for clinics, patients were ultimately recruited into DIAMOND at very low rates. Ultimately, the weak penetration of this intervention may have been related to the low reimbursement level from commercial payers and the absence of coverage for DIAMOND care for those insured by Medicare or Medicaid. In addition, DIAMOND was not a clinical trial, and as such did not have research assistants to actively identify and recruit subjects, often an arduous task in research that takes significant resources, a factor that may have also contributed to its small reach. Further, participating clinics consistently indicated that many physicians did not refer patients to DIAMOND because of clinical inertia for a nontraditional care model, disagreement with the idea that DIAMOND was needed or that it provided better care than their existing care, or a sentiment that many patients did not want or need the extra care. Moreover, most clinics were unwilling to implement an automatic opt-in process for patient participation, something that might have significantly improved recruitment. Finally, while ICSI provided clinics with feedback about their recruitment rates, feedback alone likely was not enough to change provider behaviors and workflows.
Another potential reason DIAMOND did not affect depression diagnosis rates had to do with economic changes at the time. National and global data indicate an increase in depression and suicide in western countries that began with the onset of the Great Recession in December 2007, 2 months before the first sequence of DIAMOND was initiated. [8] [9] [10] The depression rate increased particularly for men and people of racial and ethnic minorities, and was at least partially related to increased unemployment and decreased housing wealth related to the recession. [11] [12] [13] These time trends may have overwhelmed any effects of DIAMOND. However, we should note that diagnoses of major depression were increasing in our data as early as February 2006 and continued for at least 4 years, without a noticeable change in the rate of depression diagnoses with the onset of the Great Recession (or with the implementation of DIAMOND).
Although we had expected that DIAMOND implementation would affect diagnostic coding for all patients with depression, this did not happen. Rates of coding for single episodes of depression (ICD9 code 296.2) increased throughout the study period, and rates of coding for depression not otherwise specified (ICD9 code 311) decreased, but these trends were occurring before DIAMOND and were unchanged by DIAMOND implementation. Some of these coding changes may have been related to multiple efforts led by ICSI to change depression care at least 4 years before DIAMOND implementation. ICSI was conducting action groups with a large share of the primary care and behavioral health providers in Minnesota for approximately 4 years before DIAMOND started, with a primary focus on gaining acceptance of the use of the patient health questionnaire 9 and diagnosing depression more accurately. This included efforts to educate primary care providers that all health plans were paying for their care of depression and to encourage clinicians to avoid using depression NOS diagnoses unless clinically appropriate. ICSI action group members felt that depression NOS represented a heterogenous group of depression diagnoses that no one approach would likely work to improve. Instead, action groups focused on working with patients with major depression and dysthymia, where they were more confident of what to recommend. Simultaneously, the health plans in Minnesota made their own efforts to improve depression care, largely through increased services for patients with depression. Ultimately, all of these efforts may have had some effects on diagnosis and coding practices. However, DIAMOND's lack of effect on specific depression codes is likely primarily a consequence of the low rates of penetration of the intervention itself. Ultimately, it is likely that the time trend for these changes was already so strong that any effect on coding DIAMOND implementation may have had was comparably insignificant. In the end, this finding speaks to how difficult it can be to successfully influence care.
Of note, patients in DIAMOND appeared to have had more episodes of treatment intensification, at least as measured by changes between antidepressants or augmentation with a second antidepressant, suggesting that once patients were recruited into DIAMOND, there was a difference in how their depression was treated. Approximately 80% of patients receiving treatment intensification had only 1 round of such intensification, potentially indicating that these were successful treatment modifications. However, these findings should be interpreted with caution. A limitation of our data is that we do not have information on depression severity, and there was likely selection bias present, with clinicians more likely to recruit patients with more severe or treatment-resistant depression into DIAMOND. If this was the case, the higher level of treatment intensification in DIAMOND patients would have been appropriate. In contrast, it is also possible that the majority of DIA-MOND patients had only 1 treatment intensification because their treatment team failed to make further needed adjustments despite ongoing depression; again, these data do not let us assess depression response or remission.
Of note, the DIAMOND main results paper reported that remission rates for DIAMOND patients were no different than 3 comparison groups, despite patients being more satisfied with their care, suggesting that treatment intensification may not have been pursued as often as might have been warranted. 14, 15 Our finding that apparently higher rates of treatment intensification did not seem to translate into improved depression outcomes is similar to that of a study examining implementation of depression collaborative care in primary care clinics in the Veterans Administration. 16 The Veterans Administration study found that patients who received collaborative care were more likely to receive adequate doses of antidepressants (66% vs. 43%, P = 0.01), but this did not translate into differences in depression outcomes.
We recognize several limitations of our data. Given the way these data were collected, we do not have patient-level data, including patient characteristics, previous episodes of depression, or comorbid conditions, all of which can affect patient outcomes. Another important limitation is an inability to capture psychotherapy episodes, resulting in patients participating in therapy but not taking antidepressants misclassified as untreated. Our ability to measure depression treatment intensification was somewhat rudimentary, as we were unable to ascertain changes in antidepressant doses or the addition of psychotherapy. In addition, our cohort was dynamic, with members able to leave or be added over time. However, a strength of this study was our ability to examine a large cohort of patients with a reasonable duration of follow-up during a real-world implementation of the collaborative care model for depression. In addition, the staggered design of DIAMOND implementation minimized any impact of secular trends during the observation period, and the use of a DIAMOND-specific billing code allowed us to ascertain a patient's exposure to the intervention.
In conclusion, DIAMOND did not affect the overall depression recognition rates or patterns of diagnostic coding in outpatients with depression. Although DIAMOND may have had some effect on treatment intensification, we cannot rule out the possibility of selection bias influencing this finding. Our results suggest that even strongly evidencebased interventions with wide local publicity may have little contamination effects on patients not enrolled in the new care model.
